Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;70(6):e30318.
doi: 10.1002/pbc.30318. Epub 2023 Mar 27.

Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma

Rosario Aschero  1   2 , Helena Castillo-Ecija  1   2 , Merce Baulenas-Farres  1   2 , Claudia Resa-Pares  1   2 , Ana Jimenez-Cabaco  1   2 , Eva Rodriguez  3 , Carles Monterrubio  1 , Sara Perez-Jaume  1   2 , Mariona Suñol  3 , Guillermo L Chantada  1   2   4 , Cinzia Lavarino  1   2 , Jaume Mora  1   2 , Angel M Carcaboso  1   2
Affiliations

Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma

Rosario Aschero et al. Pediatr Blood Cancer. 2023 Jun.

Abstract

Background: Successful engraftment of human cancer biopsies in immunodeficient mice correlates with the poor prognosis of patients. This was reported 30 years ago for children with neuroblastoma, but the standard of care treatment evolved significantly during the last 15 years, leading to improved survival of these patients. Here, we evaluated the association of patient-derived xenograft (PDX) engraftment and prognosis in patients receiving up-to-date treatments for cancers classified as metastatic (stage M) high-risk neuroblastoma (HR-NB) by the International Neuroblastoma Risk Group Staging System (INRGSS).

Methods: We obtained biopsies from patients with stage M HR-NB. We inoculated biopsy fragments subcutaneously in mice. We studied the association of PDX engraftment with event-free survival (EFS) and overall survival (OS) of patients.

Results: Since 2009, we established 17 PDX from 97 samples of 66 patients with stage M HR-NB, with a follow-up of at least two years. Factors associated with higher probability of engraftment were the death as outcome (p = .0006) and the amplification of the gene MYCN in tumors (p = .0271). Patients whose biopsies established a PDX had significantly shorter EFS and OS (p = .0039 and .0002, respectively) than patients whose samples did not engraft. The association of PDX engraftment and OS was significant in patients without MYCN amplification (p = .0041), but not in patients with MYCN amplification (p = .2707).

Conclusion: Positive PDX engraftment is a factor related to poor prognosis and fatal outcome in patients with stage M HR-NB treated with up-to-date therapies.

Keywords: engraftment; metastatic (stage M) high-risk neuroblastoma (HR-NB); patient-derived xenograft (PDX); prognosis; survival.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998-1013.
    1. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2(2):247-250.
    1. Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338-350.
    1. Oh BY, Lee WY, Jung S, et al. Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients. Oncotarget. 2015;6(18):16059-16068.
    1. DeRose YS, Wang G, Lin YC, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17(11):1514-1520.

Publication types

Substances

LinkOut - more resources